Search Result

Results for "

PD-1/PD-L

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (100) Apoptosis (5) Aryl Hydrocarbon Receptor (1) Drug-Linker Conjugates for ADC (1) E3 Ligase Ligand-Linker Conjugates (1) Eukaryotic Initiation Factor (eIF) (1) HBV (1) Interleukin Related (1) LAG-3 (1) Ligands for Target Protein for PROTAC (2) NF-κB (1) Phosphatase (2) PROTAC Linkers (3) PROTACs (1) Target Protein Ligand-Linker Conjugates (2) TNF Receptor (1) Toll-like Receptor (TLR) (4)
By Research Areas:	Cancer (108) Infection (5) Inflammation/Immunology (26)
Click Chemistry:	Azide (1)

115

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162343

PD-1/PD-L1-IN-41

PD-1/PD-L1 Inflammation/Immunology Cancer

PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC₅₀ value of 10.2 nM .

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-N12537

PD-1/PD-L1-IN-38	PD-1/PD-L1	Cancer
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .

HY-163307

PD-1/PD-L1-IN-39	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity .

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity .

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-158052

PD-1/PD-L1 antagonist 1	PD-1/PD-L1	Cancer
PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC₅₀ of 23.78 nM .

HY-130625

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent *PD-1/PD-L1* interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model .

HY-157811

PD-1/PD-L1-IN-40	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-40 (Compound EP16) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer .

HY-152240

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity .

HY-144258

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .

HY-144447

PD-1/PD-L1-IN-17	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases .

HY-145770

PD-1/PD-L1-IN-19	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-19 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-19 blocks PD-1/PD-L1 with the IC₅₀ of 62.3 nM. PD-1/PD-L1-IN-19 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-145772

PD-1/PD-L1-IN-21	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC₅₀ of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-145773

PD-1/PD-L1-IN-22	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC₅₀ of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-145768

PD-1/PD-L1-IN-18	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC₅₀ of 1.054 μM. Antitumor Activity .

HY-129172A

PD-1/PD-L1-IN 5	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM .

HY-143305

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of *PD-1/PD-L1* interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer .

HY-145774

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1*/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice .

HY-163041

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a *PD-1/PD-L1* complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy .

HY-146740

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 ⁺ T cells and reduces T cell exhaustion .

HY-144649

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent *PD-1/PD-L1* inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs .

HY-144442

PD-1/PD-L1-IN-15	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch .

HY-144443

PD-1/PD-L1-IN-16	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch .

HY-129172

PD-1/PD-L1-IN 5 TFA	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 TFA is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM .

HY-132192

PD-1/PD-L1-IN-9	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-144746

PD-1/PD-L1-IN-26	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases .

HY-132192A

PD-1/PD-L1-IN-9 hydrochloride	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-148305

PD-1/PD-L1-IN-28	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-28 (compound 3) is an immune checkpoint inhibitor of *PD-1/PD-L1* signaling pathway (IC₅₀=0.744 µM). PD-1/PD-L1-IN-28 shows good research potential in tumor immunity .

HY-131347

PD-1/PD-L1-IN-NP19	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-NP19 is a *PD-1/PD-L1* inhibitor, with an IC₅₀ of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects .

HY-149356

PD-1/PD-L1-IN-31	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC₅₀=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .

HY-154869

PD-1/PD-L1-IN-34	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits *PD-1/PD-L1* interaction (IC₅₀=0.029 μM), with a selected binding affinity with PD-L1 (K_D=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment .

HY-132202

PD-1/PD-L1-IN-10

PD-1/PD-L1 Apoptosis Cancer

PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC₅₀ of 2.7 nM) with potent anticancer efficacy .

PD-1/PD-L1-IN-10	PD-1/PD-L1 Apoptosis	Cancer
PD-1/PD-L1-IN-10 (compound B2) is an orally active *PD-1/PD-L1* inhibitor (IC₅₀ of 2.7 nM) with potent anticancer efficacy .

HY-145239

PD-1/PD-L1-IN-13	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint *PD-1/PD-L1* inhibitor with an IC₅₀ value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 ⁺ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model .

HY-155740

PD-1/PD-L1-IN-32	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 inhibitor (IC₅₀=2.4 nM), with anticancer activity. PD-1/PD-L1-IN-32 significantly inhibits tumor growth in hPD-L1 MC38 humanized mouse model, without obvious toxicity against mouse normal ability .

HY-W457085

PD-1/PD-L1-IN-29 intermediate-2	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 intermediate-2 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-48934

PD-1/PD-L1-IN-29 intermediate-1	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 intermediate-1 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-153064

MAX-10181 PD-1/PD-L1-IN-30	PD-1/PD-L1	Cancer
MAX-10181 (PD-1/PD-L1-IN-30) is a *PD-1/PD-L1* binding inhibitor, with an IC₅₀ value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases .

HY-138407

Evixapodlin GS-4224; PD-1/PD-L1-IN 7	PD-1/PD-L1 HBV	Infection Cancer
Evixapodlin (GS-4224) is a *human PD-1/PD-L1 protein/protein interaction* inhibitor with an IC₅₀ of 0.213 nM. Evixapodlin has anticancer and antiviral functions .

HY-19991

BMS-1 Maximum Cited Publications 18 Publications Verification PD-1/PD-L1 inhibitor 1	PD-1/PD-L1 Apoptosis	Inflammation/Immunology Cancer
BMS-1 is an inhibitor of the *PD-1/PD-L1* protein/protein interaction (IC₅₀ between 6 and 100 nM) .

HY-134884

INCB086550 PD-1/PD-L1-IN-8	PD-1/PD-L1	Cancer
INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC_50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research .

HY-101058

PD1-PDL1-IN 1

PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator .

PD1-PDL1-IN 1
PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator .

HY-101058A

PD1-PDL1-IN 1 TFA	PD-1/PD-L1	Inflammation/Immunology Cancer
PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator .

HY-157569

PD1-PDL1-IN 2	PD-1/PD-L1	Cancer
PD1-PDL1-IN 2 (ZE132) is a potent and selective *PD-1/PD-L1* inhibitor, which has robust anti-tumour activity in vivo. PD1-PDL1-IN 2 promotes cytotoxic T-cell tumour infiltration and induces IL-2 expression. In addition, PD1-PDL1-IN 2 elicits strong inhibitory effects on the mRNA expression of TGF-β .

HY-160585

PD-L1/PD-1-IN-1	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of *PD-L1/PD* interaction, with IC₅₀ ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research .

HY-131183

*PROTAC PD-1/PD-L1 degrader-1*	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .

HY-N12537A

*(2R,3S)-PD-1/PD-L1-IN-38*	Aryl Hydrocarbon Receptor PD-1/PD-L1	Cancer
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 .

HY-P9902A

Pembrolizumab (anti-PD-1) 2 Publications Verification	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

486 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 486 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L079

Anti-Blood Cancer Compound Library

2676 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L007

Immunology/Inflammation Compound Library

5006 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 5006 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

HY-L109

Protein-protein Interaction Inhibitor Library

576 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 576 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein inhibitor with a K_d** value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 .

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P1812

AUNP-12 NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .

HY-P1812A

AUNP-12 TFA NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function .

HY-P10091

CD24/Siglec-10 blocking peptide, CSBP	PD-1/PD-L1	Cancer
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell .

Cat. No.	Product Name	Target	Research Area

HY-P9902A

Pembrolizumab (anti-PD-1) 2 Publications Verification	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

HY-P9971

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and *PD-L2* (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-P99641

Gilvetmab

PD-1/PD-L1 Cancer

Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

HY-P99639

Geptanolimab APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .

HY-P9972

Spartalizumab PDR001	PD-1/PD-L1	Cancer
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds *PD-1* with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and *PD-L2*. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1*. Garivulimab has antitumor activity .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific *PD-1/LAG-3* dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to *PD-1, thereby blocking the interaction of PD-1* with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P9919

Durvalumab 5 Publications Verification MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of *PD-L1* and *PD-1*. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal *PD-L1* (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

HY-P9996

Reozalimab

LY3434172
PD-1/PD-L1 Cancer

Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research .
HY-P99100

Visugromab

CTL-002
PD-1/PD-L1 Cancer

Visugromab is aGDF-15 neutralizing IgG4 mAb. Visugromab exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors .

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting *PD-L1* and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against *PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1*/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

Species:	Human (4) Rat (2) Mouse (2) Cynomolgus (2)
Tag:	His (6) Avi (1) Fc (4)
Source:	HEK293 (10)

Cat. No.	Compare	Product Name	Species	Source

HY-P73371

	PD-L2 Protein, Rat (HEK293, His) Programmed cell death 1 ligand 2; PD-1 ligand 2; PD-L2; B7-DC; CD273	Rat	HEK293
	Programmed cell death 1 ligand 2 (Pdcd1lg2, Pd-l2, B7-DC) is a member of B7 family and a ligand of programmed cell death 1. Pdcd1lg2 negatively regulates activated T cell proliferation, interferon-gamma production and interleukin-10 production in a PDCD1-independent manner, or inhibits T-cell proliferation by blocking cell cycle progression and cytokine production by interacts with PDCD1, and consequently causes cancer growth and suppresses the immune system. PD-L2 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L2 Protein, Rat (HEK293, His) is 200 a.a., with molecular weight of ~35.7 kDa.

HY-P73370

	PD-L2 Protein, Rat (HEK293, Fc) Programmed cell death 1 ligand 2; PD-1 ligand 2; PD-L2; B7-DC; CD273	Rat	HEK293
	Programmed cell death 1 ligand 2 (Pdcd1lg2, Pd-l2, B7-DC) is a member of B7 family and a ligand of programmed cell death 1. Pdcd1lg2 negatively regulates activated T cell proliferation, interferon-gamma production and interleukin-10 production in a PDCD1-independent manner, or inhibits T-cell proliferation by blocking cell cycle progression and cytokine production by interacts with PDCD1, and consequently causes cancer growth and suppresses the immune system. PD-L2 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-L2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L2 Protein, Rat (HEK293, Fc) is 219 a.a., with molecular weight of ~64.6 kDa.

HY-P77528

	PD-L2 Protein, Human (Biotinylated, HEK293, His) Programmed cell death 1 ligand 2; PD-1 ligand 2; PD-L2; B7-DC; CD273	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L2 Protein, Human (Biotinylated, HEK293, His) is 200 a.a., with molecular weight of ~24 KDa.

HY-P73369

	PD-L2 Protein, Mouse (219a.a, HEK293, His) Programmed cell death 1 ligand 2; PD-1 ligand 2; PD-L2; B7-DC; CD273	Mouse	HEK293
	PD-L2 Protein plays a critical role in the T-cell costimulatory signal, fostering proliferation and IFNG production independently of PDCD1. While interacting with PDCD1 inhibits T-cell proliferation, PD-L2 itself intricately promotes immune responses. The dynamic interplay emphasizes PD-L2's dual role in either promoting or inhibiting T-cell activation within the immune signaling network, showcasing intricate regulatory mechanisms. PD-L2 Protein, Mouse (219a.a, HEK293, His) is the recombinant mouse-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L2 Protein, Mouse (219a.a, HEK293, His) is 200 a.a., with molecular weight of 31-40 kDa.

HY-P72407

	PD-L2 Protein, Human (Biotinylated, HEK293, His-Avi) PD-1 Ligand 2; PDCD1 Ligand 2; B7-DC; CD273; PDCD1LG2; B7DC; CD273; PDCD1L2; PDL2	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of PD-L2 Protein, Human (Biotinylated, HEK293, His-Avi) is 200 a.a., with molecular weight of 38-60 kDa.

HY-P72492

	PD-L2 Protein, Human (HEK293, His) Programmed cell death 1 ligand 2; PDcd1lg2; PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (HEK293, His) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L2 Protein, Human (HEK293, His) is 200 a.a., with molecular weight of 34-50 kDa.

HY-P72493

	PD-L2 Protein, Cynomolgus (HEK293, His) Programmed cell death 1 ligand 2; PDcd1lg2; PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	Cynomolgus	HEK293
	PDCD1LG2 is an immune checkpoint receptor ligand that binds to PD-1 to activate pathways that inhibit TCR/ BCR-mediated immune cell activation. PDCD1LG2 can inhibit T-cell proliferation and inflammatory cytokine production. The expression of PDCD1LG2 on mouse tumor cells inhibits cytotoxic T-cell-mediated immune responses and can be used as a biomarker or prognostic indicator. PD-L2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-L2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L2 Protein, Cynomolgus (HEK293, His) is 200 a.a., with molecular weight of 30-40 kDa.

HY-P72491

	PD-L2 Protein, Mouse (200a.a, HEK293, Fc) Programmed cell death 1 ligand 2; PDcd1lg2; PD-1 ligand 2; PD-L2; PDCD1 ligand 2; B7-DC; CD273	Mouse	HEK293
	PD-L2 Protein plays a critical role in the T-cell costimulatory signal, fostering proliferation and IFNG production independently of PDCD1. While interacting with PDCD1 inhibits T-cell proliferation, PD-L2 itself intricately promotes immune responses. The dynamic interplay emphasizes PD-L2's dual role in either promoting or inhibiting T-cell activation within the immune signaling network, showcasing intricate regulatory mechanisms. PD-L2 Protein, Mouse (200a.a, HEK293, Fc) is the recombinant mouse-derived PD-L2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L2 Protein, Mouse (200a.a, HEK293, Fc) is 200 a.a., with molecular weight of 70-80 kDa.

HY-P70734

	PD-L2 Protein, Human (HEK293, mFc) Programmed Cell Death 1 Ligand 2; PD-1 Ligand 2; PD-L2; PDCD1 Ligand 2; Programmed Death Ligand 2; Butyrophilin B7-DC; B7-DC; CD273; PDCD1LG2; B7DC; CD273; PDCD1L2; PDL2	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (HEK293, mFc) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of PD-L2 Protein, Human (HEK293, mFc) is 200 a.a., with molecular weight of 60-90 kDa.

HY-P70964

	PD-L2 Protein, Cynomolgus (HEK293, Fc) Programmed Cell Death 1 Ligand 2; PD-1 Ligand 2; PD-L2; PDCD1 Ligand 2; Programmed Death Ligand 2; Butyrophilin B7-DC; B7-DC; CD273; PDCD1LG2; B7DC; CD273; PDCD1L2; PDL2	Cynomolgus	HEK293
	PDCD1LG2 is an immune checkpoint receptor ligand that binds to PD-1 to activate pathways that inhibit TCR/ BCR-mediated immune cell activation. PDCD1LG2 can inhibit T-cell proliferation and inflammatory cytokine production. The expression of PDCD1LG2 on mouse tumor cells inhibits cytotoxic T-cell-mediated immune responses and can be used as a biomarker or prognostic indicator. PD-L2 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-L2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L2 Protein, Cynomolgus (HEK293, Fc) is 200 a.a., with molecular weight of 60-90 kDa.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks